Prevail Therapeutics Inc. (NASDAQ:PRVL) is expected to report second quarter earnings results, before market open, on Tuesday 11th August 2020.
Analysts polled by Thomson Reuters anticipate second quarter loss of $ 0.59 per share.
Looking ahead, the full year loss are expected at $ 2.38 per share.
Previous Quarter Performance
Prevail Therapeutics Inc. disclosed loss for the first quarter of $ 0.56 per share, from the revenue of . The quarterly earnings grew 38.46 percent compared with the same quarter last year. Street analysts expected . The bottom line results street analysts by $ 0.21 or , at the same time, top line results analysts by $ 6.29 million or .
Stock Performance
According to the previous trading day, closing price of PRVL was $ 15.88, representing a 81.28 % increase from the 52 week low of $ 8.76 and a 20.44 % decrease over the 52 week high of $ 19.96.
The company has a market capital of $ 543.12 million and is part of the Healthcare sector and Biotechnology industry.
Conference Call
Prevail Therapeutics Inc. will be hosting a conference call at 7:30 AM eastern time on 11th August 2020, to discuss its 2Q20 financial results with the investment community. A live webcast with presentations will be available on the Internet by visiting the Company website www.prevailtherapeutics.com
Prevail Therapeutics Inc., a gene therapy company, focuses on developing and commercializing disease-modifying AAV-based gene therapies for patients with devastating neurodegenerative diseases. The companys lead product candidate is PR001 for the treatment of Parkinsons disease with GBA1 mutation and neuronopathic Gaucher disease. It is also developing PR006 for the treatment of frontotemporal dementia with GRN mutation and PR004 for the treatment of synucleinopathies.
